Medical device maker Boston Scientific Corp said it expects to grow faster than the overall market for implantable heart devices, which has been struggling in recent years amid weak worldwide demand.
New product launches, improved margins, plus greater participation in emerging markets were among the factors he cited as growth drivers.
Company executives said there were signs of improvement in the first quarter.
"We were encouraged but not satisfied," said Chief Financial Officer Jeff Capello, adding that he sees a return to growth in the second half of 2013.